nivolumab,ipilimumab
merck,astellas,novartis,astrazeneca,bms,pfizer,exelixis,arca biopharma,eisai,seagen,incyte,roche,ipsen
['gu ', 'nivolumab', 'hcrn,gu16,260', '/ipi', 'hcrn,gu,16,260', 'rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'thanks', 'ipilimumab', 'nivo', 'roche,(-broche),(-rocheter)', 'pfizer', 'eisai', 'bms', 'msd', 'ipsen', 'merck', 'incyte', 'bristol', 'serono', 'arca ', 'astrazeneca', 'exelixis', 'astellas', 'seattle genetics', 'arca, (-arcade)', 'novartis']
great talk ! thanks to atkins, md nivo monotherapy with salvage nivo/ipi in non-responders is an active treatment approach in treatment-na ve pts with arcc and results in substantial tfs and toxicity-free tfs.
#ascogu2023#gu23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.